
U.S. President Joe Biden is winning widespread praise from health experts for endorsing a six-month-old proposal to waive the pharmaceutical industry’s intellectual property (IP) rights on COVID-19 vaccines. But several questions remain, including how quickly Wednesday’s decision will translate to more vaccines in the developing world and whether other rich countries will join the United States in supporting Biden’s plan.